Moor Vascular Assessment System -

Moor 血管评估系统 -

基本信息

项目摘要

DESCRIPTION (provided by applicant): This proposal is for the purchase of a Moor Instruments Vascular Assessment System (VAS), which will serve 7 NIH-funded research groups. The VAS is an integrated laser Doppler imaging (LDI) device that will replace our first generation Moor LDI system, which has been working at near maximum capacity for 8 years, but is outdated and produces data of inferior quality due to the low resolution images generated. An additional limitation of the present system is the wavelength of the laser does not penetrate past the most superficial tissue layers and, therefore, does not adequately interrogate the areas of interest. Finally, the present modality does not allow real-time capture of images for determining transient changes in blood flow due to interventions. The demand for LDI on our campus continues to grow, and the proposed system will fulfill the needs of a large number of researchers by providing excellent resolution of vascular beds, allowing assessment of deep tissue microcirculatory systems and providing serial, non-invasive dynamic visualization and quantitation of blood flow, so that new applications for LDI can be accommodated or developed. The VAS can image specimens with very high resolution (less than 100 mm), penetrate up to 3 mm in depth and can capture up to 25 frames per second of video. A typical scan takes only about 15 minutes (including preparation of animal model), and the system comes with an analysis workstation to allow rapid quantitation. The enhanced capabilities of the system will better serve the needs of our vascular biology research community. Applications for the proposed facility include: 1) Assessment of stem cell-induced revascularization of ischemic tissues. 2) Stem and progenitor cell-mediated vasculogenesis in tissue and cell grafts. 3) Serial evaluation of tumor perfusion in response to anti-angiogenic agents 4) Involvement of a bone marrow-derived cell population in neovascularization. 5) Evaluate the contribution of different endothelial progenitor types in vascular remodeling and angiogenesis. 6) Determination of the molecular mechanisms that contribute to disease-associated attenuation of endothelial repair processes and vasoreactivity. The acquisition of the VAS is essential for continued progress on these and future projects requiring this state-of-the-art technology. PUBLIC HEALTH RELEVANCE: This proposal is for purchase of a new laser Doppler imaging system, which will be used to study biological specimens from several laboratories. This technology will make possible new discoveries in the areas of vascular disease, blood homeostasis, assess the activity of compounds that alter blood flow, vascular remodeling and arteriogenesis in normal and diseased tissues.
描述(由申请人提供):本提案旨在购买 Moor Instruments 血管评估系统 (VAS),该系统将为 7 个 NIH 资助的研究小组提供服务。 VAS 是一款集成激光多普勒成像 (LDI) 设备,将取代我们的第一代 Moor LDI 系统,该系统已在接近最大容量的情况下工作了 8 年,但已经过时,并且由于生成的图像分辨率低,产生的数据质量较差。本系统的另一个限制是激光的波长不能穿透最表层的组织层,因此不能充分询问感兴趣的区域。最后,目前的模式不允许实时捕获图像来确定由于干预导致的血流的瞬时变化。 我们校园对 LDI 的需求持续增长,所提出的系统将通过提供出色的血管床分辨率、允许评估深层组织微循环系统并提供串行、非侵入性动态可视化和分析来满足大量研究人员的需求。血流定量,以便适应或开发 LDI 的新应用。 VAS 可以以非常高的分辨率(小于 100 毫米)对样本进行成像,穿透深度可达 3 毫米,并且可以捕获每秒高达 25 帧的视频。一次典型的扫描仅需约15分钟(包括动物模型的准备),并且系统配有分析工作站,可实现快速定量。该系统增强的功能将更好地满足我们血管生物学研究界的需求。拟议设施的应用包括:1)评估干细胞诱导的缺血组织血运重建。 2)组织和细胞移植物中干细胞和祖细胞介导的血管生成。 3) 抗血管生成剂对肿瘤灌注的连续评价。 4) 骨髓来源的细胞群参与新血管形成。 5)评估不同内皮祖细胞类型在血管重塑和血管生成中的贡献。 6) 确定导致疾病相关的内皮修复过程和血管反应性减弱的分子机制。 收购 VAS 对于这些和未来需要这种最先进技术的项目的持续进展至关重要。 公共健康相关性:该提案旨在购买新的激光多普勒成像系统,该系统将用于研究多个实验室的生物样本。这项技术将在血管疾病、血液稳态、评估改变正常和患病组织中血流、血管重塑和动脉生成的化合物的活性方面取得新的发现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brian H. Johnstone其他文献

Brian H. Johnstone的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brian H. Johnstone', 18)}}的其他基金

A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance
一种新颖且临床可行的联合疗法,将已故供体骨髓与供体匹配的间充质干细胞相结合,以建立免疫耐受
  • 批准号:
    10081139
  • 财政年份:
    2020
  • 资助金额:
    $ 13.04万
  • 项目类别:
Developing a bank of purified myeloid progenitor cells as a bridging therapy for transient pancytopenia resulting from radiation injury
开发纯化的骨髓祖细胞库作为放射损伤引起的短暂性全血细胞减少症的桥接疗法
  • 批准号:
    10081134
  • 财政年份:
    2020
  • 资助金额:
    $ 13.04万
  • 项目类别:
A Novel and Clinically Feasible Co-therapy of Deceased Donor Bone Marrow Combined With Donor-Matched Mesenchymal Stem Cells to Establish Immune Tolerance
一种新颖且临床可行的联合疗法,将已故供体骨髓与供体匹配的间充质干细胞相结合,以建立免疫耐受
  • 批准号:
    10212956
  • 财政年份:
    2020
  • 资助金额:
    $ 13.04万
  • 项目类别:
Validation of a Stroke Therapy Comprised of Synergistic Stem Cell-Derived Factors
包含协同干细胞衍生因子的中风疗法的验证
  • 批准号:
    8980800
  • 财政年份:
    2015
  • 资助金额:
    $ 13.04万
  • 项目类别:

相似国自然基金

髋关节撞击综合征过度运动及机械刺激动物模型建立与相关致病机制研究
  • 批准号:
    82372496
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
基于中医经典名方干预效应差异的非酒精性脂肪性肝病动物模型证候判别研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    53 万元
  • 项目类别:
    面上项目
利用肝癌动物模型开展化学可控的在体基因编辑体系的研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
雌激素抑制髓系白血病动物模型中粒细胞异常增生的机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
无菌动物模型与单细胞拉曼技术结合的猴与人自闭症靶标菌筛选及其机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

First-in-class TREM-1 inhibitors for neovascular retinal diseases
用于治疗新生血管性视网膜疾病的一流 TREM-1 抑制剂
  • 批准号:
    10597284
  • 财政年份:
    2023
  • 资助金额:
    $ 13.04万
  • 项目类别:
Extracellular Matrix Impacts Angiogenesis and Growth Plate Repair
细胞外基质影响血管生成和生长板修复
  • 批准号:
    10668056
  • 财政年份:
    2023
  • 资助金额:
    $ 13.04万
  • 项目类别:
Fibrin-CAR-T cells therapies to enhance efficacy in glioblastoma treatments
纤维蛋白-CAR-T 细胞疗法可增强胶质母细胞瘤治疗的疗效
  • 批准号:
    10515887
  • 财政年份:
    2022
  • 资助金额:
    $ 13.04万
  • 项目类别:
Elucidation of novel anti-angiogenic therapies for the prevention and treatment of neovascular glaucoma
阐明预防和治疗新生血管性青光眼的新型抗血管生成疗法
  • 批准号:
    10491662
  • 财政年份:
    2021
  • 资助金额:
    $ 13.04万
  • 项目类别:
Mechanisms of post-preeclampsia hypertension
子痫前期高血压的机制
  • 批准号:
    10541890
  • 财政年份:
    2021
  • 资助金额:
    $ 13.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了